In the year of 2017, the instrument industry is surging, and acquisitions and mergers and acquisitions are endless

M&A is regarded as an investment activity and has become more and more popular among enterprises in recent years. For a long time, enterprises with advantages in technology, scale, and capital will take an undisputed position in the industry consolidation, while weaker companies will either be merged or eliminated. In the current fierce competition in the social market, companies with certain strengths in the industry are seeking listings or being acquired by listed companies, hoping to capitalize on capital market financing and other resource advantages to rapidly increase their own strengths and gain greater market share.

Mergers and acquisitions can bring new development space to enterprises and help improve their product lines and expand their markets. However, mergers and acquisitions can not only create such opportunities for development, but also have some operational risks. Therefore, the instrument brand must see the industry and market development trends according to its own strength and make appropriate decisions for itself. Strong alliances and complementary resources can also be a development path. Together, we reviewed the significant corporate mergers and acquisitions that occurred in the instrument industry in 2017.

Sartorius Acquires Essen BioScience

As a leading partner in biopharmaceuticals and laboratory technology, Sartorius signed a deal to acquire Essen BioScience in the United States on March 3, 2017. Sartorius will spend $320 million to acquire Essen BioScience, a pioneer and leader in cell analysis technology and instrumentation for drug discovery and basic research. In the high-tech industry, large-scale technology companies always acquire the key technologies they need through acquisitions, and this acquisition will significantly expand the Sartorius bioanalysis business scope, enabling Sartorius to provide its customers with the most extensive , the most innovative cell analysis service in the industry, and powering Sartorius' continued growth.

BD Medical will acquire Budd Medical or be ranked fifth in the global medical and medical industry

On April 24, BD Medical announced that it will acquire Bard Medical Technology Corp. for a $24 billion structure through cash and stock exchanges. According to the 2016 annual report of the two companies, BD's annual sales were US$12.483 billion, and Bard’s revenue for the year was US$3.714 billion. If the acquisition is successful, both sales will reach $16.197 billion. This figure is enough to rank among the world's top physicians and surpass Siemens. Under the wave of development of biomedical technology, major medical device companies have used acquisition methods to achieve business expansion and ensure that they will obtain more benefits in the future medical device market. And the tendency of corporate mergers and acquisitions is no longer a small, innovative company, but a giant with leading edge in the field of medical devices.

Emerson Acquires Pentair’s Valves and Controls for $3.15 Billion

On April 28, Emerson announced that it had officially completed the acquisition of Pentair’s valve and control business for $3.15 billion. Mr. David N. Farr, Chairman and CEO of Emerson stated: “This investment enables us to continue to develop in the global automation field and expand our leading position in the key service markets such as chemicals, power, oil refining, oil and gas, etc.” As a veteran instrument and equipment Emerson, a manufacturing company, has always been committed to providing customers with global technology solutions. Today, it has generously acquired Pentair’s valve and control business for US$3.15 billion, demonstrating Emerson’s development ambitions in the automation field. It is believed that this acquisition will provide Emerson with chemical, power, The leading position in the refining services market helps.

WuXi Biology's pre-clinical drug development platform merged with WuXi PharmaTech

On May 15th, WuXi PharmaTech, a leading global pharmaceuticals, biotechnology and medical device open capabilities and technology platform company, announced that its acquisition of HDBiosciences (HDB), a pre-clinical drug R&D outsourcing company, was officially completed. Headquartered in Shanghai, Huiyuan Biosciences is a leading preclinical R&D service platform in the industry. It mainly provides drug target verification, in-vitro drug efficacy evaluation based on microplates, active compound recognition, lead compound discovery, and in vivo pharmacology studies. Pre-drug development services. Its customer base includes all the top 10 pharmaceutical companies in the world. Through this acquisition, WuXi PharmaTech will further strengthen the drug discovery capabilities for target discovery and optimization from target verification, and WuXi PharmaTech's integrated R&D service platform will be further improved and expanded.

China's largest overseas merger in history: China Chemicals and Syngenta completed delivery

On June 8, China National Chemical Corporation (ChemChina) and Swiss agrochemical and seed company Syngenta announced that the former had completed the second delivery of the latter's offer. Up to now, China Chemical has owned 94.7% of Syngenta shares. At this point, the largest overseas merger and acquisition in the history of Chinese companies has been officially completed. In April this year, China, the United States, the European Union and Mexico and other anti-monopoly regulatory agencies have all approved China Chemical to acquire Syngenta. In May this year, Syngenta officially announced that its shareholders had accepted the offer of China Chemical. On June 8, China Chemical announced the completion of the second delivery of the Syngenta offer. According to a statement issued by China National Chemicals, the shareholders of Syngenta who accepted the offer after May 4, 2017 have received a consideration of US$465/share on June 7, 2017, and the American Depositary Receipts (ADS) holders received the same day. To 93 US dollars / ADS price. China National Chemical Industry Co., Ltd. said that after the related laws and regulations permit, Syngenta shares will be delisted from the Swiss Exchange and the American Depositary Receipts (ADS) will be withdrawn from the New York Stock Exchange. In recent years, China Chemical has successfully acquired several leading companies in France, the United Kingdom, Israel, Italy, Germany and other countries.

PerkinElmer $1.3 Billion Acquisition of Aumont Medical

On June 19, 2017, PerkinElmer announced that the company has signed a definitive agreement to acquire EUROIMMUN Medical Laboratory Diagnostics AG. According to the agreement, PerkinElmer will receive a 100% stake in Aumont. Based on all issued shares, the total purchase price of the transaction is approximately $1.3 billion in cash. PerkinElmer has done a good job in life sciences, optoelectronics, and analytical instruments. Nowadays, the global medical market is positive. A series of patents and technologies in the medical field of Aumont Medical can fit well with PerkinElmer's medical field layout. It is believed that this acquisition will also allow PerkinElmer to be in the life science field. Go further.

80 Million Pounds Hitachi Formally Acquires Oxford Instruments Industrial Analysis Business

On July 5th, Hitachi Hi-Tech Group acquired the industrial analysis business of Oxford Instruments, a well-known scientific instrument company, for a market value of GBP 80 million. Oxford Instruments' Industrial Analysis Department formally became part of Hitachi High-Tech Group. The new company will provide customers in the industrial field with more analytical solutions. The newly-established Hitachi High-Tech Analytical Science Company is a collection of Hitachi High-Tech's existing scientific instrumentation product lines, and has worked closely with Oxford Instruments for 45 years with industry customers and has extensive experience in the development of innovative analytical instruments and services. This cooperation will make the company's product line more abundant, more contact with customers and more opportunities to meet customer needs.

Agilent acquires Cobalt for 40 million pounds to enter the Raman spectrum market

On July 7, 2017, Agilent Technologies announced that it has acquired Oxfordshire CobaltLightSystems (“Cobalt”), a supplier of high resolution Raman spectroscopy for the pharmaceutical industry application market and public safety, for a £40million cash purchase. Cobalt's solution portfolio accelerates its entry into the high-growth Raman spectrum market and will expand Agilent's value proposition for pharmaceutical and biopharmaceutical customers. Raman spectroscopy is one of the fastest growing parts of spectroscopy. This acquisition enabled Agilent customers to acquire the most advanced Raman spectroscopy technology, and also enabled Agilent to enter this fast-growing field immediately, with highly competitive differentiated products.

Philips has completed acquisition of Spectranetics, a manufacturer of minimally invasive surgical medical equipment in the United States

On August 9, Philips announced that it has completed the acquisition of Spectranetics, a manufacturer of minimally invasive surgical medical equipment in the United States, and that Spectronictic's performance has been incorporated into Philips' image-guided therapeutic business since that day. "Spectranetics is highly complementary to Philips' image-guided therapeutics business and its addition will further strengthen Philips' leadership position in the 6 billion-euro image guidance market," said Philips CEO Marriott. "This acquisition will enable Philips to achieve a strategic expansion in therapeutic equipment. Spectranetics' highly-competitive product range, coupled with Philips' interventional imaging systems and devices, navigation software and service portfolio, will help clinicians determine the right heart and circumference Vascular therapy, which in turn enhances patient care."

Valuation of 800 million Hymer Technologies plans to acquire not less than 60% of Si Tan's shares

Haimo Technology's operating revenue in 2016 was 285 million yuan, and the sales revenue of Xitan in 2016 was 228 million yuan. Therefore, the acquisition of the equity of Stantech Instruments by Hymer Technology constitutes a major asset restructuring. According to the performance forecast released by Hymer Technology, it is expected that the profit for the first half of this year will decline, or a year-on-year decrease, to 1.74 million yuan -2.91 million yuan. If successful acquisition of Stantech Electronics, Haimo Technology will actively contribute profits and achieve a substantial increase in performance. For this acquisition, Stantech has made a performance gambling. If the transaction is completed in 2017, it promises that Xitan’s net profit will continue to be 42% in 2017 compared to its own profit last year. High growth.

55.42% share delivery, Tianrui Instrument Holdings Co., Ltd.

The latest news shows that 55.42% of shares are delivered! Focus on the field of environmental monitoring and food safety, and specialize in providing online environmental monitoring systems, pre-processing systems, conventional analysis systems and related consumables, as well as various types of integrated detection solutions and related technology value-added services. Rui Instrument Holdings subsidiary. Tianrui Instrument holds a total of 19,608,104 shares of Qihe Keyi, accounting for 55.42% of the total shares of Qihe Keyi. Adhering to the business philosophy and development philosophy of “building a strong quality and pursuing a spirit of cooperation”, we have strived to become an industry leader as soon as possible. Today, we will continue to use Skyray's environmental protection platform to continue to contribute to China's environmental protection business.

With the in-depth interpretation of the capital market, the competition laws for the survival of the fittest in the industry are becoming increasingly prominent day by day, expanding market share and providing immediate benefits to customers. M&A is nothing but the general trend. As one of the main themes in the instrument market for breakthroughs and development in recent years, M&A has become a new engine for economic growth. With the intensified industry consolidation, the industry giants have become more and more obvious in scale, which is also a development opportunity for SMEs.

Through mergers and acquisitions is a good way for instrument companies to obtain technology and fresh blood. From the merger and acquisition of old-name instrument companies, we can see its unique M&A vision and accurate judgments on market development trends. Today, after experiencing the wave of mergers and acquisitions in 2017, will instrument companies be dead or will it set off a new wave of mergers and acquisitions? We will wait and see.